Novartis Plans Exit from Indian Unit in ₹1,446 Crore Deal
Novartis India shares have surged following the announcement of its Swiss parent company's plan to exit its Indian operations for ₹1,446 crore. The move has triggered an open offer for shareholders.
Novartis India shares saw a significant increase after the company's Swiss parent announced its decision to exit the Indian market through a deal worth ₹1,446 crore. This exit plan has resulted in a surge of approximately 20% in the Mumbai-listed shares of Novartis India.
Details of the Exit Plan
The Swiss pharmaceutical company intends to sell its entire 70.68% stake in Novartis India. This sale will trigger an open offer for existing shareholders at a price of ₹860.64 per share. The deal, valued at around $159 million, is part of Novartis' broader strategy to streamline its operations and focus on core markets. According to a report by The Hindu, the announcement has garnered attention from investors, leading to the notable rise in share prices.
Market Reaction
The market has responded positively to the news, reflecting investor confidence in the potential for future growth following the exit. In addition to Novartis, ChrysCapital and two other firms have launched an open offer for Novartis India, further indicating interest in the company’s assets. The developments surrounding Novartis India highlight a significant shift in the company's operational strategy within the Indian pharmaceutical landscape.